Champions Oncology, Inc. (CSBR) Q1 FY2027 earnings

Reported results

• Revenue of $15.2 million, an increase of 8.8% year over year (GAAP)
• Oncology services margin of 51%, compared with 43% in the prior-year period (non-GAAP)
• Adjusted EBITDA of $671,000, compared with $59,000 in the prior-year period (non-GAAP)
• Net loss of $426,000, compared with a net loss of $466,000 in the prior-year period (GAAP)
• Cost of oncology revenue was $7.5 million, a decrease of $461,000 or 5.8%, compared to $8.0 million in the prior-year period (GAAP)
• Cash and cash equivalents of $4.4 million with no debt at quarter end

Notes

The release contains reconciliations of non-GAAP measures (Adjusted EBITDA, Adjusted EPS, and Oncology Services Profit/Margin) to GAAP results. Stock-based compensation of $766,000 and depreciation and amortization of $314,000 are included in the current-quarter net loss.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-09-10 (8-K, Item 2.02). Read the original filing on sec.gov.